Catalyst Pharmaceuticals (CPRX) Change in Account Payables (2010 - 2026)

Catalyst Pharmaceuticals has reported Change in Account Payables for 17 years, with the latest figure at -$4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 24.93% year-over-year to -$4.1 million; the trailing twelve-month figure through Mar 2026 stood at -$4.0 million (down 532.26% YoY), and the FY2025 full-year result was -$5.4 million, down 399.83% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$4.1 million, down from $2.1 million in the prior quarter.
• The five-year high for Change in Account Payables was $10.2 million in Q4 2023, with the low at -$5.7 million in Q2 2025.
• Historically, Change in Account Payables has averaged $257823.5 across 5 years, with a median of $214000.0 in 2022.
• The largest YoY upside for Change in Account Payables was 8937.5% in 2022 against a maximum downside of 873.7% in 2022.
• Catalyst Pharmaceuticals' Change in Account Payables stood at $1.4 million in 2022, then jumped by 605.19% to $10.2 million in 2023, then sank by 50.67% to $5.0 million in 2024, then tumbled by 58.13% to $2.1 million in 2025, then plunged by 292.36% to -$4.1 million in 2026.
• The last three Change in Account Payables figures came in at -$4.1 million (Q1 2026), $2.1 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.